{
 "PrintNo":"A62","Session":2023,"Chamber":"ASSEMBLY","BillType":"Assembly","Published":"2022-12-29T09:43:23.826132Z",
 "Status":"IN_ASSEMBLY_COMM","Committee":"Insurance",
 "Milestones":[{"Type":"IN_ASSEMBLY_COMM","Date":"2024-01-03","Committee":"Insurance"}],
 "Actions":[
  {"Text":"REFERRED TO INSURANCE","Date":"2023-01-04","Chamber":"ASSEMBLY"},
  {"Text":"REFERRED TO INSURANCE","Date":"2024-01-03","Chamber":"ASSEMBLY"}
 ],
 "Sponsors":[{"ID":1258,"Name":"Nader Sayegh","Short":"SAYEGH"}],
 "Title":"Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology",
 "Summary":"Provides for patient access to FDA approved abuse-deterrent technology to help combat opioid abuse.",
 "LawSection":"Public Health Law","LawCode":"Amd ยง273, Pub Health L; add ยง3216-a, Ins L",
 "ActClause":"AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs",
 "SameAsPrintNo":"S6332-2023","PreviousVersions":["A4667-2021"]
}